Over the last 12 months the Opthea Ltd (ASX: OPT) share price has been one of the best performers on the All Ordinaries index.
During this time the shares of the developer of novel biologic therapies for the treatment of eye diseases have risen a whopping 370%.
Why has the Opthea share price almost quintupled in 12 months?
Investors have been scrambling to buy the company’s shares following the release of the results of a key study in August.
That study related to its OPT-302 combination therapy for treatment-naïve patients with wet age-related macular degeneration (AMD).
As you might have guessed from the share price reaction, OPT-302 (2.0 mg) combination therapy showed statistical superiority for the most accepted and sensitive primary efficacy outcome.
Whilst it remains early days, the results are pointing to a bright future for OPT-302. After all, the current standard of care treatments for wet AMD generated sales of US$3.7 billion in 2018.
But it doesn’t stop there. Opthea also has its eyes on the Diabetic Macular Edema (DME) market. Management notes that there is potential for the therapy to be used for DME, which is an even more lucrative market.
According to the company, the current standard of care generates sales of US$6.2 billion per annum at present. Combined, this gives OPT-302 a market opportunity of almost US$10 billion.
Is Opthea a buy?
Given the success of its study and its massive market opportunity, I think Opthea could be a great option for investors that have a high tolerance for risk.
I’m not alone with this view. A note out of Goldman Sachs late last year reveals that its analysts have the company on their conviction buy list with a $5.20 price target. This compares to its current share price of $3.10.
Goldman Sachs believes that “OPT-302 has multi-billion dollar potential.”
Its analysts said: “As successful as current treatments have been, they only inhibit up to two of the factors responsible for the disease (VEGF-A/B). Over half of patients do not achieve significant vision gains, and a quarter experience continued vision loss. OPT-302 is intended for use in combination with these treatments, blocking a further two factors (VEGF-C/D), hence targeting improved outcomes via a more complete blockade.”
In light of this, it has suggested that in the future it could achieve “non-risk-adjusted peak sales of US$5.0bn (US$2.0bn risk-adjusted), of which US$3.4bn relates to wAMD (US$1.7bn).”
In addition to Opthea, I think industry peers Next Science Ltd (ASX: NXS) and Paradigm Biopharmaceuticals Ltd (ASX: PAR) would also be worth watching very closely in 2020.
The post The Opthea share price is up 370% in 12 months: Can it go higher? appeared first on Motley Fool Australia.
But if they're too risky for your liking then don't miss out on these growth shares that are trading at very attractive prices.
Our Motley Fool experts have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020